P J Bevis
Overview
Explore the profile of P J Bevis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
403
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Adebanjo O, Koval A, Moonga B, Wu X, Yao S, Bevis P, et al.
Biochem Biophys Res Commun
. 2000 Jul;
273(3):884-9.
PMID: 10891341
We report the molecular cloning and functional characterization of a novel member of the CD38 family of cyclic ADP-ribose (cADPr)-generating cyclases. We cloned a cDNA insert that encoded a 298-amino-acid-long...
2.
Adebanjo O, Biswas G, Moonga B, Anandatheerthavarada H, Sun L, Bevis P, et al.
Am J Physiol Renal Physiol
. 2000 May;
278(5):F784-91.
PMID: 10807590
We report the first biochemical and functional characterization of inositol trisphosphate receptors (IP(3)Rs) and ryanodine receptors (RyRs) in the nuclear membrane of bone-forming (MC3T3-E1) osteoblasts. Intact nuclei fluoresced intensely with...
3.
Adebanjo O, Anandatheerthavarada H, Koval A, Moonga B, Biswas G, Sun L, et al.
Nat Cell Biol
. 1999 Nov;
1(7):409-14.
PMID: 10559984
Nucleoplasmic calcium ions (Ca2+) influence nuclear functions as critical as gene transcription, apoptosis, DNA repair, topoisomerase activation and polymerase unfolding. Although both inositol trisphosphate receptors and ryanodine receptors, types of...
4.
Sun L, Adebanjo O, Moonga B, Corisdeo S, Anandatheerthavarada H, Biswas G, et al.
J Cell Biol
. 1999 Sep;
146(5):1161-72.
PMID: 10477767
The multifunctional ADP-ribosyl cyclase, CD38, catalyzes the cyclization of NAD(+) to cyclic ADP-ribose (cADPr). The latter gates Ca(2+) release through microsomal membrane-resident ryanodine receptors (RyRs). We first cloned and sequenced...
5.
Boulton-Jones J, Geddes C, Heinzel G, Turck D, Nehmiz G, Bevis P
Br J Clin Pharmacol
. 1997 Jan;
43(1):35-40.
PMID: 9056050
Aims: The aim of the present study was to determine how the pharmacokinetics of meloxicam are affected by kidney dysfunction and consequently to define the appropriate dose for the use...
6.
Prouse P, Bevis P, Bluhmki E, Distel M
Clin Ther
. 1996 May;
18(3):429-39.
PMID: 8829018
This 12-week, open-label, multicenter study assessed the safety, tolerability, and efficacy of the tablet formulation of meloxicam 15 mg, a new, nonsteroidal antiinflammatory drug (NSAID), in patients with confirmed osteoarthritis...
7.
Bevis P, Bird H, Lapham G
Br J Rheumatol
. 1996 Apr;
35 Suppl 1:56-60.
PMID: 8630639
Meloxicam is a new non-steroidal anti-inflammatory drug (NSAID) which has shown potent anti-inflammatory properties but good gastrointestinal (GI) renal tolerability. The safety and tolerability profile of orally administered meloxicam 15...
8.
Wojtulewski J, Schattenkirchner M, Barcelo P, Le Loet X, Bevis P, Bluhmki E, et al.
Br J Rheumatol
. 1996 Apr;
35 Suppl 1:22-8.
PMID: 8630632
Meloxicam is a new non-steroidal anti-inflammatory drug (NSAID) which preferentially inhibits cyclooxygenase-2 over cyclooxygenase-1. A double-blind parallel-group trial compared meloxicam 7.5 mg once daily (n = 199) with naproxen 750...
9.
Zaidi M, Towhidul Alam A, Bax C, Shankar V, Bevis P, Huang C, et al.
Methods Mol Biol
. 1994 Jan;
27:279-93.
PMID: 8298697
No abstract available.
10.
Zaidi M, Pazianas M, Shankar V, Bax B, Bax C, Bevis P, et al.
Exp Physiol
. 1993 Nov;
78(6):721-39.
PMID: 8311941
Bone resorption appears to be dependent on a range of processes. It requires an adequate number of osteoclasts to access bone mineral. These osteoclasts must be activated by a mechanism...